VERTEX PHARMACEUTICALS INC / MA (VRTX) Earnings
VERTEX PHARMACEUTICALS INC / MA's most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 3, 2026
From the latest earnings 8-K
Revenue · FY2025
$12.00B
▲ 8.9%YoY
Diluted EPS · FY2025
$15.32
▲ 836.5%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from VRTX's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $12.00B | $3.95B | — | $15.32 | $3.19B | 34.8% | +8.9% |
| FY2024 | $11.02B | -$535.60M | — | $-2.08 | -$790.30M | -2.1% | +11.7% |
| FY2023 | $9.87B | $3.62B | — | $13.89 | $3.34B | 38.8% | +10.5% |
| FY2022 | $8.93B | $3.32B | — | $12.82 | $3.93B | 48.2% | +17.9% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 3, 2026 | 8-K (2.02) | 0000875320-26-000256EDGAR |
| May 4, 2026 | 8-K (2.02) | 0000875320-26-000171EDGAR |
| Feb 12, 2026 | 8-K (2.02) | 0000875320-26-000034EDGAR |
| Nov 3, 2025 | 8-K (2.02) | 0000875320-25-000230EDGAR |
| Aug 4, 2025 | 8-K (2.02) | 0000875320-25-000213EDGAR |
| May 5, 2025 | 8-K (2.02) | 0000875320-25-000171EDGAR |
| Feb 10, 2025 | 8-K (2.02) | 0000875320-25-000029EDGAR |
| Nov 4, 2024 | 8-K (2.02) | 0000875320-24-000221EDGAR |
Never miss a VRTX filing.
Get an email when VRTX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Sep 16, 2026Source: SEC EDGAR.